Beating estimates for revenues and profits, Californian biotech Amgen (Nasdaq: AMGN) presented strong results for the final quarter and full year of 2023 on Wednesday.
For the fourth quarter, total revenues increased 20% to $8.2 billion, driven by 23% volume growth, partially offset by slightly lower prices.
Touting broad-based growth, the firm said nine brands achieved record sales in the quarter, including double-digit growth for Repatha (evolocumab), Evenity (romosozumab-aqqg), Prolia (denosumab) and Blincyto (blinatumomab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze